Introduction
HCoV-OC43 encodes two accessory genes, ns2 and ns12.9 (20). The ns2 gene, pair for rOC43-ns2FusionRluc and rOC43-ns2DelRluc (5′-GTG TAA GCC CAA
183
GGT TGA GAT AG-3′) / (5′-GTC GTT CAG ATT GTA ATC ATA TTG -3′), and
184
another for rOC43-ns129FusionRluc and rOC43-ns129DelRluc (5′-CAT ATG AAT
185
ATT ATG TAA AAT GGC -3′)/ (5′-GCC ATA AAC ATT TAA CTC CTG TC -3′). The
186
PCR products were subjected to electrophoresis on a 1% agarose gel.
187
Real-time PCR. Semi-quantitative PCR was performed using the One Step
188
SYBR PrimeScript RT-PCR Kit (Takara) according to the manufacturer's instructions.
189
Fold-induction values were calculated using the 2 −ΔΔCt method and mRNA expression 190 was normalized to GAPDH. Genomic RNA copies of HCoV-OC43-WT or 191 rOC43-ns2DelRluc was quantified using a previously described quantitative RT-PCR
192
as described previously (24). All primers are available in Table S1 . by low-speed centrifugation at 3,000 rpm for 12 min to obtain passage 1 virus (P1).
250
After 5 rounds of serial passages, the rOC43-ns2DelRluc was passaged to P5. rOC43-ns12.9StopRluc) or in-frame insertion of the Rluc gene into ns2 or ns12.9
262 genes (rOC43-ns2FusionRluc and rOC43-ns12.9FusionRluc), respectively ( Fig. 1 ).
263
The in vitro growth characteristics of the reporter viruses were analyzed by 
283
Rluc activity in cells infected with reporter viruses was also characterized.
284 Surprisingly, the viral titer of rOC43-ns2DelRluc was 4-fold lower than that of the 285 rOC43-ns2FusionRluc at 144 hpi, but showed robust Rluc expression levels, with
286
Rluc activity 18-fold higher than that of the rOC43-ns2FusionRluc (Fig. 2D) . (Fig. 2E ). In addition, we observed high levels of Rluc proteins in 296 the lysates of cells infected with rOC43-ns12.9StopRluc, but no ns12.9-Rluc fusion 297 proteins were detected in the lysates of rOC43-ns12.9FusionRluc-infected cells, 298 perhaps due to its low Rluc expression levels at 96 hpi (Fig. 2F) . These results
299
correlated with the Rluc activity detected at the corresponding hpi (Fig. 2D ). rOC43-ns12.9FusionRluc showed 4-to 6-fold reduction in Rluc activity during the 13 324 passages (Fig. 3C) . To investigate whether mutations were introduced during the 327 Surprisingly, the Rluc gene remained intact in the genome of all rHCoVs-OC43 as no 328 smaller PCR product was detected over the 13 passages (Fig. 3D) . However, sequence the Rluc expression cassette of three rHCoVs-OC43 (see Fig. S1 and Table S2 ).
332
It is worth mentioning that the replacement of accessory genes with the Rluc gene 333 resulted in rHCoVs-OC43 with higher genetic stability when compared with in-frame 334 insertions of the Rluc gene (Table S2 ). Because the rOC43-ns2DelRluc showed robust showed no inhibitory effect at the same concentrations (Fig. 4B) . Moreover, a similar 353 decrease in viral copy numbers was observed in the two viruses in the presence of 354 increasing levels of chloroquine or ribavirin, indicating that deletion of the ns2 gene 355 had no effect on the sensitivity of rOC43-ns2DelRluc to the antiviral drugs.
356
To verify whether the Rluc activity of rOC43-ns2DelRluc could be used for 357 antiviral drug screening, we analyzed the antiviral activity of chloroquine and 358 ribavirin against rOC43-ns2DelRluc in parallel using luciferase-based reporter assays.
359
As expected, Rluc activity was reduced in the presence of increasing levels of 360 chloroquine or ribavirin in a dose-dependent manner ( Fig. 4C and Fig. 4D high basal levels at 8 and 12 hpi and becoming barely detectable at 24 h (Fig. 6A ).
401
These results suggested that phosphorylation of PKR and eIF2α were increased at the Fig. 7F and 7G ). 
452
These data demonstrated the feasibility of using rOC43-ns2DelRluc for drug 453 screening and identifying antiviral host factors. HCoV-OC43 encodes two accessory genes, ns2 and ns12.9; however, the 471 biological functions of these HCoV-OC43 accessory genes remain poorly understood.
472
In this study, we generated a variety of luciferase-based rHCoVs-OC43 by genetic Chloroquine, a clinically approved drug, appeared to be a broad-spectrum CoVs drug, 
